Smartphone maker HTC Corp (宏達電) has set its sights on earning an operating license from the Food and Drug Administration to commercialize a new medical virtual-reality (VR) product in the first quarter of next year.
Dubbed Surgical Theater, the VR product could begin to be adopted in clinical use and provide HTC with new revenue streams from the healthcare sector, the company said at a news conference yesterday.
The company also announced that it has sold Taipei Medical University its latest VR offering, 3D Organon, a bundle of 10 Vive Pro VR headsets that provide visualized anatomy information for education.
Photo by Kao Shih-ching, taipei Times
Medical students usually learn human anatomy from 2D models and diagrams in textbooks, or from donated cadavers, which are often in short supply, university Department of Anatomy professor Chang Hung-ming (張宏名) told the Taipei Times.
With the VR teaching system, students can see a computerized simulation that more clearly depicts human anatomy, especially the nervous system, whose components are thin and mostly hidden behind muscles and cavities, Chang said.
A 360o view allows users to see the human body from all angles to better understand how everything is connected, and they can also peel back layers or isolate 4,000 body parts to have a specific view, HTC healthcare division DeepQ director Jerry Cheng (鄭志偉) said.
“Users can even go through the virtual body to have a clear look inside at parts such as the spine and cavities,” he said.
However, it is hard for a VR system to substitute for “silent teachers” (大體老師) — people who have donated their bodies to medical schools — as “students cannot touch or feel the elasticity of muscles in virtual reality,” Chang said.
Besides Taipei Medical University, HTC has also sold 3D Organon to Tri-Service General Hospital and Taipei Municipal Wanfang Hospital, which plan to use the product for shared decisionmaking with patients, Cheng said.
While the firm has begun marketing 3D Organon, which costs about NT$100,000 per unit, HTC said it has also applied for a license for Surgical Theater, which would cost significantly more.
The company has received three medical appliance licenses from the US Food and Drug Administration for Surgical Theater, which provides accurate information that can even be used to help surgeons navigate operations, Cheng said.
As HTC has already conducted clinical trials in the US, it expects to receive approval from the Taiwanese agency by the first quarter of next year, Cheng said, adding that it would market the product to domestic hospitals first and expects to see revenue from the healthcare sector soar.
Three experts in the high technology industry have said that US President Donald Trump’s pledge to impose higher tariffs on Taiwanese semiconductors is part of an effort to force Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) to the negotiating table. In a speech to Republicans on Jan. 27, Trump said he intends to impose tariffs on Taiwan to bring chip production to the US. “The incentive is going to be they’re not going to want to pay a 25, 50 or even a 100 percent tax,” he said. Darson Chiu (邱達生), an economics professor at Taichung-based Tunghai University and director-general of
‘LEGACY CHIPS’: Chinese companies have dramatically increased mature chip production capacity, but the West’s drive for secure supply chains offers a lifeline for Taiwan When Powerchip Technology Corp (力晶科技) entered a deal with the eastern Chinese city of Hefei in 2015 to set up a new chip foundry, it hoped the move would help provide better access to the promising Chinese market. However, nine years later, that Chinese foundry, Nexchip Semiconductor Corp (合晶集成), has become one of its biggest rivals in the legacy chip space, leveraging steep discounts after Beijing’s localization call forced Powerchip to give up the once-lucrative business making integrated circuits for Chinese flat panels. Nexchip is among Chinese foundries quickly winning market share in the crucial US$56.3 billion industry of so-called legacy
Hon Hai Precision Industry Co (鴻海精密) is reportedly making another pass at Nissan Motor Co, as the Japanese automaker's tie-up with Honda Motor Co falls apart. Nissan shares rose as much as 6 percent after Taiwan’s Central News Agency reported that Hon Hai chairman Young Liu (劉揚偉) instructed former Nissan executive Jun Seki to connect with French carmaker Renault SA, which holds about 36 percent of Nissan’s stock. Hon Hai, the Taiwanese iPhone-maker also known as Foxconn Technology Group (富士康科技集團), was exploring an investment or buyout of Nissan last year, but backed off in December after the Japanese carmaker penned a deal
WASHINGTON POLICY: Tariffs of 10 percent or more and other new costs are tipped to hit shipments of small parcels, cutting export growth by 1.3 percentage points The decision by US President Donald Trump to ban Chinese companies from using a US tariff loophole would hit tens of billions of dollars of trade and reduce China’s economic growth this year, according to new estimates by economists at Nomura Holdings Inc. According to Nomura’s estimates, last year companies such as Shein (希音) and PDD Holdings Inc’s (拼多多控股) Temu shipped US$46 billion of small parcels to the US to take advantage of the rule that allows items with a declared value under US$800 to enter the US tariff-free. Tariffs of 10 percent or more and other new costs would slash such
RSS